Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astragalus + Gemcitabine in pancreatic cancer
NCT06234072Phase 2Not yet recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- Feb 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of astragalus injection + doushen tang in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Shenzhen University General Hospital. Primary endpoint: Objective Response Rate at 3 years. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
astragalus injection + doushen tang
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06234072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234072.